Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every launch, funding round, exec hire, and M&A move on Valneva SE — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Valneva SE announces robust and lasting immune response in adolescents one year after single vaccination with its chikungunya vaccine IXCHIQ®.

Jan 20, 2025•over 1 year ago
Pays de la LoireManufacturingBiotechnologyHealth CareMedical

Product Description

Valneva SE has revealed positive Phase 3 results for its single-dose chikungunya vaccine, IXCHIQ®, showing a 98.3% seroresponse rate one year post-vaccination among adolescents. This data supports regulatory submissions for age extension in the US, Europe, and Canada and could lead to market authorization in Brazil.

Company Information

Company

Valneva SE

Location

Pays de la Loire, France

About

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company takes a highly specialized and targeted approach, applying deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

Predictive Intelligence
Strategic

ML-powered predictions for Valneva SE's next move

Learn about Strategic plan

Product Launch Insights

Based on market data
Market expansion signals
New product launches often coincide with market expansion initiatives

Related People

Suggested for you

Sign in to view contact details